Temperature Management Devices Are Hot

Doctors have long theorized that being able to precisely warm (hyperthermia) and cool (hypothermia) patients, depending on their conditions and surroundings, would be beneficial in a variety of neurological and cardiovascular procedures. This has given rise to a group of medical device companies formed in the mid-to-late 1990s dedicated to developing temperature management systems. The big question has ben whether clinical data would validate the bets these companies made in this space. Early clinical data released recently has been positive, and large companies are interested in this area, sparking the first major temperature management deal.

One person was trapped in the snow; another fell into an icy lake; the tales have been told of people suffering some type of neurological or cardiac event in which damage was minimized because of exposure to extreme cold. Doctors have long theorized that being able to precisely warm (hyperthermia) and cool (hypothermia) patients, depending on their conditions and surroundings, would be beneficial in a variety of neurological and cardiovascular procedures. Between 1996 and 1998 these hypotheses gave rise to a group of medical device start-ups dedicated to developing temperature management systems, including Medivance Inc. , Cardeon Corp. , Radiant Medical Inc. , and Innercool Therapies Inc. Other companies operating in this space include Alsius Inc. and Seacoast Technologies Corp. (See "Medical Device's Ice Age," IN VIVO, January 2001 Also see "Medical Device's Ice Age" - In Vivo, 1 January, 2001.; "Medivance: Climate Control for the Body," IN VIVO, July 2001 Also see "Medivance: Climate Control for the Body" - In Vivo, 1 July, 2001.;"Innercool Therapies Inc.," START-UP, January 2000 Also see "Innercool Therapies Inc." - Medtech Insight, 1 January, 2000.;"Radiant Medical Inc.," START-UP, May 2000 Also see "Radiant Medical Inc." - Medtech Insight, 1 May, 2000.;"Cardeon Corp.," START-UP, October 2000 Also see "Cardeon Corp." - Medtech Insight, 1 October, 2000..)

The big question in temperature management has been whether clinical data would validate the bets these companies made in this space. Since these therapies are used in high-risk patients, which have suffered stroke, cardiac arrest, and heart attack/myocardial infarction (MI), clinical trials are long and difficult, and data has been slow in coming

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

More from R&D

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By 

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.

Thousands Of Cardiac Digital Twins Reveal Novel Connections With Mental Health

 

King’s College London, Imperial College London and The Alan Turing Institute constructed cardiac digital twins at scale, creating over 3,400, in a new study using UK Biobank data published in Nature Cardiovascular Research on 16 May.

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.